| Elotuzumab therapy for relapsed or refractory multiple myeloma S Lonial, M Dimopoulos, A Palumbo, D White, S Grosicki, I Spicka, ... New England Journal of Medicine 373 (7), 621-631, 2015 | 1504 | 2015 |
| Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial S Lonial, BM Weiss, SZ Usmani, S Singhal, A Chari, NJ Bahlis, A Belch, ... The Lancet 387 (10027), 1551-1560, 2016 | 972 | 2016 |
| Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma L Benboubker, MA Dimopoulos, A Dispenzieri, J Catalano, AR Belch, ... New England Journal of Medicine 371 (10), 906-917, 2014 | 908 | 2014 |
| Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a … JF San-Miguel, VTM Hungria, SS Yoon, M Beksac, MA Dimopoulos, ... The lancet oncology 15 (11), 1195-1206, 2014 | 891 | 2014 |
| Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label … PG Richardson, A Oriol, M Beksac, AM Liberati, M Galli, F Schjesvold, ... The Lancet Oncology 20 (6), 781-794, 2019 | 350 | 2019 |
| Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma T Facon, MA Dimopoulos, A Dispenzieri, JV Catalano, A Belch, M Cavo, ... Blood, The Journal of the American Society of Hematology 131 (3), 301-310, 2018 | 280 | 2018 |
| Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label … S Grosicki, M Simonova, I Spicka, L Pour, I Kriachok, M Gavriatopoulou, ... The Lancet 396 (10262), 1563-1573, 2020 | 254 | 2020 |
| Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study NJ Bahlis, MA Dimopoulos, DJ White, L Benboubker, G Cook, M Leiba, ... Leukemia 34 (7), 1875-1884, 2020 | 246 | 2020 |
| Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study M Rieger, A Österborg, R Pettengell, D White, D Gill, J Walewski, E Kuhnt, ... Annals of oncology 22 (3), 664-670, 2011 | 245 | 2011 |
| Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX MA Dimopoulos, J San-Miguel, A Belch, D White, L Benboubker, G Cook, ... haematologica 103 (12), 2088, 2018 | 236 | 2018 |
| Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group CI Chen, CT Kouroukis, D White, M Voralia, E Stadtmauer, AK Stewart, ... Journal of clinical oncology 25 (12), 1570-1575, 2007 | 222 | 2007 |
| Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 … MV Mateos, H Nahi, W Legiec, S Grosicki, V Vorobyev, I Spicka, ... The lancet haematology 7 (5), e370-e380, 2020 | 209 | 2020 |
| A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients A Belch, W Shelley, D Bergsagel, K Wilson, P Klimo, D White, A Willan British Journal of Cancer 57 (1), 94-99, 1988 | 194 | 1988 |
| Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT‐2 follow‐up and post‐hoc analyses on progression‐free … MA Dimopoulos, S Lonial, D White, P Moreau, A Palumbo, J San‐Miguel, ... British journal of haematology 178 (6), 896-905, 2017 | 162 | 2017 |
| Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose … PG Richardson, S Jagannath, P Moreau, AJ Jakubowiak, MS Raab, ... The Lancet Haematology 2 (12), e516-e527, 2015 | 159 | 2015 |
| Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma NJ Bahlis, H Sutherland, D White, M Sebag, S Lentzsch, R Kotb, ... Blood, The Journal of the American Society of Hematology 132 (24), 2546-2554, 2018 | 151 | 2018 |
| A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute … AK Stewart, S Trudel, NJ Bahlis, D White, W Sabry, A Belch, T Reiman, ... Blood, The Journal of the American Society of Hematology 121 (9), 1517-1523, 2013 | 150 | 2013 |
| Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study MA Dimopoulos, S Lonial, D White, P Moreau, K Weisel, J San-Miguel, ... Blood cancer journal 10 (9), 91, 2020 | 122 | 2020 |
| Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T‐cell lymphoma E Toumishey, A Prasad, G Dueck, N Chua, D Finch, J Johnston, ... Cancer 121 (5), 716-723, 2015 | 119 | 2015 |
| Interim report of a phase 2 clinical trial of lenalidomide for T‐cell non‐Hodgkin lymphoma G Dueck, N Chua, A Prasad, D Finch, D Stewart, D White, R van der Jagt, ... Cancer 116 (19), 4541-4548, 2010 | 115 | 2010 |
